louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03316755: Risk Perception of Periodontal Disease
Official title: Risk Perception of Periodontal Disease: A Randomised Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontal Diseases
Lead sponsor: University of Benin
Sponsor class: OTHER
First posted: 2017-10-20
Enrollment: 300
Sex: ALL
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomised
Primary purpose: PREVENTION

Brief summary: This study aimed at understanding the impact of educational pamphlet on Risk Perception of Periodontal Disease using A Randomised Clinical Trial model among patients in a Nigerian outpatient dental clinic

Detailed description: This study aimed at understanding the impact of educational pamphlet on Risk Perception of Periodontal Disease using A Randomised Clinical Trial model among patients in a Nigerian outpatient dental clinic. The outcome will help activate a success oriented periodontal disease prevention model

Eligibility criteria: Inclusion Criteria:

* consenting dental patients

Exclusion Criteria:

* non consenting dental patients

Primary outcomes:
measure: Risk perception
timeFrame: 1month
Secondary outcomes:
Other outcomes:
Locations:
city: Benin City
country: Nigeria
facility: UBenin
state: Edo State
Study officials:
affiliation: UBTH
name: Clement C Azodo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02440555: Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose
Official title: Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose Compared to Current Screening in the Priority Health Area of Saint-Etienne and the Sainté Diabète Network.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes
Keywords: diabetes, capillary blood glucose, self-administered questionnaire
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
Collaborators: name: Sanofi
First posted: 2015-05-12
Enrollment: 1305
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population is composed by patients living in the Saint-Etienne area, 45 years or older, not known as diabetics, and viewed in a pharmacy or a hospital.

Brief summary: Type 2 diabetes is the chronic disease with the most important development in France, and particularly in the Saint-Etienne area due to his specific population.

Different studies showed the interest of screening targeted on high risk population to reduce cardiovascular risks and mortality.

The current screening recommandation is an opportunist targeted screening on population older than 45 years with risk factors by a fasting glucose every 3 years, and a communautaire screening targeted on population older than 45 years suffering precarity with or without risk factors by capillary blood glucose or fasting glucose.

The objective of the Sainté Diabete network is to optimize the screening of diabetics, their follow-up and their treatments. Using a self-administered questionnaire during a medical visit could be a simple, cheap and efficient tool to detect diabetics as soon as possible.


Eligibility criteria: Inclusion Criteria:

* Man or woman
* 45 years or older
* Signed informed consent

Exclusion Criteria:

* fasting glucose performed in the last 2 years
* diabetes history
* not living in Saint-Etienne

Primary outcomes:
measure: Sensitivity of detection of type 2 diabetes
timeFrame: Day 1 (inclusion day)
Secondary outcomes:
measure: Specificity of detection of type 2 diabetes
timeFrame: Day 1 (inclusion day)
measure: To evaluate the cost of the targeted screening and the screening accessibility to population from the priority health area of Saint-Etienne
timeFrame: Month 2
measure: To evaluate the numbers of patients screened by self-administered questionnaire and diagnosed as diabetics using fasting glucose.
timeFrame: Month 2
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: Chu Saint-Etienne
Study officials:
affiliation: Université de Saint-Etienne
name: Christophe BOIS, Pr
role: STUDY_DIRECTOR
References:
Clinical trial NCT01024855: Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Myopia
Hyperopia
Astigmatism
Lead sponsor: Abbott Medical Optics
Sponsor class: INDUSTRY
First posted: 2009-12-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A new multi-purpose solution (MPS)was clinically evaluated against Opti-Free RepleniSH MPS at specific time points over the course of four days. The study was conducted with PureVision lenses.


Eligibility criteria: Inclusion Criteria:

* were at least 18 years old;
* were experienced contact lens wearers;
* were correctable to at least 20/40 or better in both eyes with contact lenses;
* were in good general health, with healthy eyes (other than requiring vision correction);
* had not worn lenses for at least 12 hours before each baseline visit;
* had a corneal staining score no greater than Grade 1 in either eye at time of enrollment;
* had previously used an MPS or hydrogen peroxide solution successfully.

Exclusion Criteria:

* had a confirmed diagnosis of Sjögren's syndrome or other condition that results in a chronic and/or pathologic dry eye condition;
* required concurrent ocular medication or have used ocular medication within 24 hours of entering the study;
* had a known sensitivity or intolerance to any MPS, study products or ingredient(s);
* were currently participating in any other clinical study;
* had a condition or are in a situation that, in the investigator's opinion, may put them at significant risk, confound the study results, or interfere significantly with their participation in the study.

Primary outcomes:
measure: Number of Eyes With No Change in Corneal Staining
timeFrame: Change from baseline after 1, 2, 4 and 6+ hours of wear
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Ana
country: United States
facility: Abbott Medical Optics Inc.
state: California
Study officials:
References:
Clinical trial NCT01247155: First Postoperative Day Review After Uneventful Phacoemulsification
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Phacoemulsification
Complications
BCVA
Lead sponsor: Veroia General Hospital
Sponsor class: OTHER
First posted: 2010-11-24
Sex: ALL
Minimum age (years): 65
Maximum age (years): 90
Standard ages: OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 291 consecutive patients who underwent uneventful phacoemulsification cataract surgery were randomized into two groups: i) Next day review (NDR group, n=146) and ii) No next day review (NNDR group, n=145).

Brief summary: The purpose of this randomized trial was to examine the value of the review on the first postoperative day after uneventful phacoemulsification cataract surgery.


Eligibility criteria: Inclusion Criteria:

Exclusion Criteria:

Exclusion criteria were the following:

i) intra-operative complications, such as posterior capsule rupture, vitreous loss, lost nucleus, zonule dehiscence and wound leak,

ii) inadequate social support for overnight care at home,

iii) severely limited visual potential in the fellow eye,

iv) uveitis or ocular trauma,

v) severe systemic diseases limiting activity,

vi) patients with learning disability or dementia.

Primary outcomes:
measure: Best corrected visual acuity
Secondary outcomes:
Other outcomes:
Locations:
city: Veroia
country: Greece
facility: General Hospital of Veroia
state: Imathia
Study officials:
References:
citation: Chatziralli IP, Sergentanis TN, Kanonidou E, Papazisis L. First postoperative day review after uneventful phacoemulsification cataract surgery: is it necessary? BMC Res Notes. 2012 Jun 27;5:333. doi: 10.1186/1756-0500-5-333.
Clinical trial NCT03713255: Mid-point Transverse Process to Pleura Block for Breast Cancer Surgery: A Randomized Controlled Trial
Official title: Analgesic Benefits of the Novel Mid-point Transverse Process to Pleura (MTP) Block for Ambulatory Breast Cancer Surgery: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Cancer
Acute Pain
Anesthesia
Keywords: Regional Anesthesia
Paravertebral Block
Breast Cancer Surgery
MTP block
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2018-10-19
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective, randomized, quadruple-blinded, three arm parallel group clinical trial.
Primary purpose: TREATMENT

Brief summary: This study will compare the analgesic effects of midpoint transverse process to pleura (MTP) block to control as well as thoracic paravertebral block.

Detailed description: Paravertebral blocks (PVBs) are frequently used for regional anesthesia for breast surgery. Ultrasound-guided paravertebral block is an advanced skill. The needle tip can be difficult to visualize with ultrasound, and the proximity to neurovascular structures as well as the pleura presents a risk of neurovascular injection and pneumothorax respectively. The midpoint transverse-process to pleura (MTP) block incorporates a novel needle endpoint that is technically easier to achieve and more distant from neurovascular structures and the pleura compared to traditional PVB. This study will compare the analgesic effects of MTP block to control and PVB.

Eligibility criteria: Inclusion Criteria:

* English or French Speaking
* Scheduled for major breast surgery
* ASA physical status classification I-III
* BMI \<30kg/m2

Exclusion Criteria:

* Prior ipsilateral breast surgery
* Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
* Contraindications to regional anesthesia
* Patient refusal of regional technique
* Chronic pain disorder
* Chronic opioid use
* Inability to provide informed consent

Primary outcomes:
measure: Postoperative analgesia during the first 24 hours.
timeFrame: 48 hours
Secondary outcomes:
measure: Post-operative quality of recovery during the first 24 hours.
timeFrame: 48 hours
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: The Ottawa Hospital
state: Ontario
Study officials:
affiliation: Ottawa Hospital, Ottawa Hospital Research Institute
name: Ioana Costache, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03077555: Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception
Official title: Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception Containing Estradiol Hemihydrate Compared to Ethinyl Estradiol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Ovulation Inhibition
Keywords: quick starting contraception
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2017-03-13
Enrollment: 69
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two intervention groups
Primary purpose: OTHER

Brief summary: Quick starting combined oral contraception containing estradiol hemihydrate/nomegestrol acetate is effective to inhibit ovulation in healthy reproductive age women and non-inferiority to combined oral contraception containing ethinyl estradiol/gestodene.

Detailed description: This study is a randomized control, non-inferiority trial which compare the proportion of ovulation between two oral combined pills when delay starting the first tablet at mid-follicular phase of menstrual cycle in 18 - 40 year old, healthy women with prior normal and regular periods. Participations will be undergone trans-vaginal or trans-rectal ultrasonography between day 1 - 3 of menstrual period for evaluation of ovarian follicle/cyst (if present). Only women who have normal looking of ovaries without dominant ovarian follicle will be included in study-protocol. Immediately after trans-vaginal/trans-rectal ultrasound between day 7 - 9 of menstrual period, all participants will be randomly assigned to receive one pack of investigated pills (1.5 mg estradiol hemihydrate/2.5 mg nomegestrol acetate or 20 mcg ethinyl estradiol/75 mcg gestodene) and to take the first tablet under direct observation by research-nurse. Participants will take one consecutive tablet at about the same time each day until complete pack. The next appointments will be every 2 - 3 days to monitor ovarian function by using Hoogland score until ovulation or follicular quiescence will be presented. The last visit will be about 1 week after complete pack to monitor adverse effect and safety through out the protocol.

Eligibility criteria: Inclusion Criteria:

* healthy women, age 18 - 40 years
* prior normal and regular interval of menstruation

Exclusion Criteria:

* current breast feeding women
* within 1 month period of child-delivery or miscarriage
* body mass index 30 kg/m2 or more
* contraindicated to use combined hormonal contraception
* current using other hormonal drugs that affect ovulation function

Primary outcomes:
measure: ovulation inhibition
timeFrame: 1 month
Secondary outcomes:
measure: follicular development
timeFrame: through study completion, an average of 1 month
Other outcomes:
Locations:
city: Bangkok Noi
country: Thailand
facility: Siriraj Hospital
state: Bangkok
Study officials:
References:
Clinical trial NCT00386555: A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Official title: Phase 2 Study of CP-868,596 + Docetaxel, AG-013736 + Docetaxel, or CP-868,596 + AG-013736 + Docetaxel and of Docetaxel Alone in Patients With Stage IIIb or IV Non-Small Cell Lung Cancer.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Lead sponsor: Arog Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2006-10-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.


Eligibility criteria: Inclusion Criteria:

* Platinum-pretreated patients with advanced stage IIIb or IV NSCLC

Exclusion Criteria:

* Centrally-located tumors

Primary outcomes:
measure: Determine the anti-tumor efficacy of CP 868,596 plus docetaxel, AG 013736 plus docetaxel, CP 868,596 plus AG 013736 plus docetaxel, and docetaxel alone in patients with advanced NSCLC based on objective tumor response (CR and PR) rate
Secondary outcomes:
measure: Determine the safety and tolerability of the combination of daily CP 868,596 and docetaxel on an every 3 week schedule
measure: Determine the safety and tolerability of the combination of daily AG 013736 and docetaxel on an every 3 week schedule
measure: Determine the safety and tolerability of both CP 868,596 and AG 013736 given together with docetaxel on an every 3 week schedule
measure: Assess additional evidence of anti-tumor activity as measured by duration of objective response, progression-free survival, and one-year survival (OS1year)
measure: Evaluate the pharmacokinetics (PK) of AG 013736 and CP 868,596 when given together with and without docetaxel
measure: Evaluate the PK of CP 868,596 when given in combination with docetaxel
measure: Evaluate the PK of docetaxel when given in combination with CP 868,596, or CP 868,596 plus AG 01373
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT01001455: Clinical Test for Armed-used Blood Pressure Monitor With Preformed Cuff
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Blood Pressure
Keywords: BP
Lead sponsor: Andon Health Co., Ltd
Sponsor class: INDUSTRY
First posted: 2009-10-26
Enrollment: 90
Sex: ALL
Minimum age (years): 23
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: resident of a community.

Brief summary: The purpose of this study is to monitor the blood pressure level of the patient using a preformed cuff ranged 22 cm-36 cm.


Eligibility criteria: Inclusion Criteria:

* cuff circumference:22cm-36cm

Exclusion Criteria:

* None

Primary outcomes:
measure: level of blood pressure
timeFrame: 10S
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05056155: Systane Complete Multi-symptom Relief
Official title: Systane Complete Multi-symptom Relief
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye Disease
Keywords: Eye drops
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2021-09-24
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate effective symptom relief with the use of Systane Complete among subjects with dry eye disease (DED).

Detailed description: Subjects will be expected to attend a screening/baseline visit and one additional visit at Day 28 (± 2 days), with a telephone call visit conducted at Day 14 (± 2 days). Individual duration of subject participation will be approximately 28 days.

Eligibility criteria: Key Inclusion Criteria:

* Able to understand and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form.
* Willing and able to attend all study visits as required per protocol.
* Have dry eye symptoms as specified in the protocol.
* Willing to discontinue use of all habitual artificial tear supplements for the entire study duration.
* Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

* Ocular conditions as specified in the protocol.
* Contact lens use within one week prior to screening visit.
* Use of medications as specified in the protocol.
* Pregnant or breast feeding.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Change from Baseline at Day 28 in IDEEL-SB Question "Sore"
timeFrame: Baseline (Day 0), Day 28
measure: Change from Baseline at Day 28 in IDEEL-SB Question "Stinging"
timeFrame: Baseline (Day 0), Day 28
measure: Change from Baseline at Day 28 in IDEEL-SB Question "Burning"
timeFrame: Baseline (Day 0), Day 28
measure: Change from Baseline at Day 28 in IDEEL-SB Question "Tired Eyes"
timeFrame: Baseline (Day 0), Day 28
measure: Change from Baseline at Day 28 in DEQ-5 Question "Watery"
timeFrame: Baseline (Day 0), Day 28
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Alcon Investigator 1455
state: Missouri
city: Granville
country: United States
facility: Alcon Investigator 8046
state: Ohio
city: Powell
country: United States
facility: Alcon Investigator 6313
state: Ohio
city: Austin
country: United States
facility: Alcon Investigator 8175
state: Texas
Study officials:
affiliation: Alcon Research, LLC
name: Clinical Trial Lead, Ocular Health
role: STUDY_DIRECTOR
References:
Clinical trial NCT00303355: Measurement of Jugular Venous Pulse in Critically Ill Patients.
Official title: An Evaluation of the Utility of Clinical Examination for the Measurement of Jugular Venous Pulse in Critically Ill Patients.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Jugular Venous Pulse Measurement in Critically Ill Patients
Keywords: jugular venous pulse
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2006-03-16
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: To assess the utility of clinical bedside examination for the measurement of jugular venous pulse in critically ill patients.

Detailed description: Procedures: All patients with central venous catheters (CVP) will undergo physical examination of the jugular veins, while blinded to the actual CVP measured from the catheter. Clinicians with various experience levels (attending physician, fellow, resident physician, 4th year medical student) will participate.

The following clinical data will be obtained: Demographic data such as age, sex, weight and diagnosis will be collected. Each clinician's bedside CVP will be recorded from the bedside monitor. Clinicians will be blinded to bedside monitor.

Eligibility criteria: Inclusion Criteria:

* All patients admitted to the ICU who have existing central venous catheters.

Exclusion Criteria:

* Patients admitted to the ICU who do not have existing central venous catheters

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: J P Kress, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vinayak AG, Levitt J, Gehlbach B, Pohlman AS, Hall JB, Kress JP. Usefulness of the external jugular vein examination in detecting abnormal central venous pressure in critically ill patients. Arch Intern Med. 2006 Oct 23;166(19):2132-7. doi: 10.1001/archinte.166.19.2132.